Published in Europace on May 15, 2011
Recurrent Hospitalization Among Patients With Atrial Fibrillation Undergoing Intracoronary Stenting Treated With 2 Treatment Strategies of Rivaroxaban or a Dose-Adjusted Oral Vitamin K Antagonist Treatment Strategy. Circulation (2016) 1.43
Safety and efficacy of dronedarone in the treatment of atrial fibrillation/flutter. Clin Med Insights Cardiol (2011) 0.93
Acute effects of intravenous dronedarone on electrocardiograms, hemodynamics and cardiac functions in anesthetized dogs. J Vet Med Sci (2015) 0.79
Cost considerations in the management of atrial fibrillation - impact of dronedarone. Clinicoecon Outcomes Res (2012) 0.77
Hospitalization: a relevant endpoint in atrial fibrillation management? Europace (2011) 0.76
Management of atrial fibrillation: focus on the role of dronedarone. Open Access Emerg Med (2011) 0.75
Current issues in atrial fibrillation. ISRN Cardiol (2012) 0.75
Managing atrial fibrillation in the elderly: critical appraisal of dronedarone. Clin Interv Aging (2011) 0.75
Comparisons of hospitalization rates among younger atrial fibrillation patients receiving different antiarrhythmic drugs. Circ Cardiovasc Qual Outcomes (2015) 0.75
A Review of the Relationship of Atrial Fibrillation and Acute Coronary Syndrome. Curr Emerg Hosp Med Rep (2016) 0.75
Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation (2006) 11.78
Lifetime risk for development of atrial fibrillation: the Framingham Heart Study. Circulation (2004) 8.80
Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med (2009) 8.51
Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet (2010) 8.17
The natural history of atrial fibrillation: incidence, risk factors, and prognosis in the Manitoba Follow-Up Study. Am J Med (1995) 6.49
Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Europace (2010) 6.31
Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med (2008) 6.17
Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet (2008) 5.03
A short-term, randomized, double-blind, parallel-group study to evaluate the efficacy and safety of dronedarone versus amiodarone in patients with persistent atrial fibrillation: the DIONYSOS study. J Cardiovasc Electrophysiol (2010) 3.24
Population prevalence, incidence, and predictors of atrial fibrillation in the Renfrew/Paisley study. Heart (2001) 2.78
Stroke patients with atrial fibrillation have a worse prognosis than patients without: data from the Austrian Stroke registry. Eur Heart J (2004) 2.63
Increasing trends in hospitalization for atrial fibrillation in the United States, 1985 through 1999: implications for primary prevention. Circulation (2003) 2.61
Antiarrhythmic drugs for maintaining sinus rhythm after cardioversion of atrial fibrillation: a systematic review of randomized controlled trials. Arch Intern Med (2006) 2.05
Alternative endpoints for mortality in studies of patients with atrial fibrillation: the AFFIRM study experience. Heart Rhythm (2004) 1.70
Rising rates of hospital admissions for atrial fibrillation. Epidemiology (2003) 1.62
Cardiovascular hospitalization as a surrogate endpoint for mortality in studies of atrial fibrillation: report from the Stockholm Cohort Study of Atrial Fibrillation. Europace (2011) 1.54
Efficacy of dofetilide in the treatment of atrial fibrillation-flutter in patients with reduced left ventricular function: a Danish investigations of arrhythmia and mortality on dofetilide (diamond) substudy. Circulation (2001) 1.51
Changing trends of hospital utilization in patients after their first episode of atrial fibrillation. Am J Cardiol (2008) 1.17
Trends in hospital activity, morbidity and case fatality related to atrial fibrillation in Scotland, 1986--1996. Eur Heart J (2001) 1.15
SR 33589, a new amiodarone-like antiarrhythmic agent: electrophysiological effects in anesthetized dogs. J Cardiovasc Pharmacol (1995) 1.13
Rationale and design of ATHENA: A placebo-controlled, double-blind, parallel arm Trial to assess the efficacy of dronedarone 400 mg bid for the prevention of cardiovascular Hospitalization or death from any cause in patiENts with Atrial fibrillation/atrial flutter. J Cardiovasc Electrophysiol (2007) 0.99
Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med (2011) 23.50
Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N Engl J Med (2009) 11.49
Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med (2013) 11.14
Subclinical atrial fibrillation and the risk of stroke. N Engl J Med (2012) 11.11
A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest (2010) 10.29
Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction. N Engl J Med (2004) 10.02
Apixaban in patients with atrial fibrillation. N Engl J Med (2011) 9.97
Dronedarone in high-risk permanent atrial fibrillation. N Engl J Med (2011) 8.93
Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med (2009) 8.51
A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med (2002) 8.37
Cardiac-resynchronization therapy for mild-to-moderate heart failure. N Engl J Med (2010) 8.28
Lenient versus strict rate control in patients with atrial fibrillation. N Engl J Med (2010) 8.17
2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol (2010) 7.54
Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation (2011) 6.48
Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med (2008) 6.17
Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter. N Engl J Med (2007) 5.78
Randomized Trial of Benznidazole for Chronic Chagas' Cardiomyopathy. N Engl J Med (2015) 5.31
Effects of CYP2C19 genotype on outcomes of clopidogrel treatment. N Engl J Med (2010) 4.73
Rimonabant for prevention of cardiovascular events (CRESCENDO): a randomised, multicentre, placebo-controlled trial. Lancet (2010) 4.72
Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity. N Engl J Med (2015) 4.50
Atrial fibrillation management: a prospective survey in ESC member countries: the Euro Heart Survey on Atrial Fibrillation. Eur Heart J (2005) 4.46
Effects of antidepressant treatment following myocardial infarction. Br J Psychiatry (2007) 4.44
Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis. J Am Coll Cardiol (2005) 4.40
Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) randomized trial. Circulation (2012) 4.33
2007 focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol (2008) 3.70
Prevention of atrial fibrillation: report from a national heart, lung, and blood institute workshop. Circulation (2009) 3.50
Long-term risk of recurrent atrial fibrillation as documented by an implantable monitoring device: implications for optimal patient care. J Am Coll Cardiol (2004) 3.50
Newly identified events in the RE-LY trial. N Engl J Med (2010) 3.35
Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial. Lancet Neurol (2010) 3.26
Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction. Circulation (2004) 3.05
Intracranial hemorrhage in atrial fibrillation patients during anticoagulation with warfarin or dabigatran: the RE-LY trial. Stroke (2012) 3.02
Microvolt T-wave alternans physiological basis, methods of measurement, and clinical utility--consensus guideline by International Society for Holter and Noninvasive Electrocardiology. J Am Coll Cardiol (2011) 3.00
Allelic variants in long-QT disease genes in patients with drug-associated torsades de pointes. Circulation (2002) 2.98
Sudden cardiac death prediction and prevention: report from a National Heart, Lung, and Blood Institute and Heart Rhythm Society Workshop. Circulation (2010) 2.94
Evaluation of the accuracy of gadolinium-enhanced cardiovascular magnetic resonance in the diagnosis of cardiac sarcoidosis. J Am Coll Cardiol (2005) 2.93
Cardiac resynchronization therapy for patients with left ventricular systolic dysfunction: a systematic review. JAMA (2007) 2.93
Chronic vagus nerve stimulation: a new and promising therapeutic approach for chronic heart failure. Eur Heart J (2010) 2.86
Meta-analysis of clinical characteristics of 299 carriers of LMNA gene mutations: do lamin A/C mutations portend a high risk of sudden death? J Mol Med (Berl) (2004) 2.81
Placebo-controlled, randomized clinical trial of azimilide for prevention of ventricular tachyarrhythmias in patients with an implantable cardioverter defibrillator. Circulation (2004) 2.81
ACC/AHA/HRS 2008 guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: executive summary. Heart Rhythm (2008) 2.75
Cardiac biomarkers are associated with an increased risk of stroke and death in patients with atrial fibrillation: a Randomized Evaluation of Long-term Anticoagulation Therapy (RE-LY) substudy. Circulation (2012) 2.74
Management and outcomes of major bleeding during treatment with dabigatran or warfarin. Circulation (2013) 2.72
Fish oil and postoperative atrial fibrillation: the Omega-3 Fatty Acids for Prevention of Post-operative Atrial Fibrillation (OPERA) randomized trial. JAMA (2012) 2.66
Implantable cardioverter-defibrillator shock prevention does not reduce mortality: a systemic review. Heart Rhythm (2012) 2.65
The Long-Term Multicenter Observational Study of Dabigatran Treatment in Patients With Atrial Fibrillation (RELY-ABLE) Study. Circulation (2013) 2.64
Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion. Circulation (2011) 2.61
Progression from paroxysmal to persistent atrial fibrillation clinical correlates and prognosis. J Am Coll Cardiol (2010) 2.59
Dabigatran versus warfarin: effects on ischemic and hemorrhagic strokes and bleeding in Asians and non-Asians with atrial fibrillation. Stroke (2013) 2.52
Management of chronic heart failure guided by individual N-terminal pro-B-type natriuretic peptide targets: results of the PRIMA (Can PRo-brain-natriuretic peptide guided therapy of chronic heart failure IMprove heart fAilure morbidity and mortality?) study. J Am Coll Cardiol (2010) 2.50
Cardiac involvement in patients with pulmonary sarcoidosis assessed at two university medical centers in the Netherlands. Chest (2005) 2.50
2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (update on dabigatran): a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. J Am Coll Cardiol (2011) 2.48